Angle PLC Notice of Results (5452M)
January 09 2019 - 2:00AM
UK Regulatory
TIDMAGL
RNS Number : 5452M
Angle PLC
09 January 2019
For Immediate Release 9 January 2019
ANGLE plc
("ANGLE" or "the Company")
Notification of Interim Results and Webcast
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, will be releasing its interim results for the six months
ended 31 October 2018 on Thursday 31 January 2019.
A meeting for analysts will be held at 12.30pm on 31 January
2019 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate
Street, London EC1A 4HD.
A live webcast of the analyst meeting will also be available on
ANGLE's Investor Centre page,
http://www.angleplc.com/investor-information/investor-centre/.
Please log on to the web address approximately 5 minutes before
12.30pm on the day of the results.
A recording of the webcast will also be made available on
ANGLE's website, www.angleplc.com, following the results
meeting.
For further information:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Stephanie Cuthbert, Ciara
Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. CTCs enable the complete
picture of a cancer to be seen as they allow DNA, RNA and protein
analysis and the live cells harvested can be cultured. Parsortix is
the subject of 21 granted patents in Europe, the United States,
Canada, India, China, Japan and Australia and three extensive
families of patents are being progressed worldwide. The system is
based on a microfluidic device that captures live cells based on a
combination of their size and compressibility. The Parsortix system
has a CE Mark in Europe for the indicated use and FDA clearance is
in process for the United States with a 400 subject study in
metastatic breast cancer. ANGLE is seeking to be the first ever FDA
cleared CTC harvesting system and only the third ever FDA cleared
liquid biopsy test. ANGLE has undertaken 400 subject clinical
verification studies in an ovarian cancer pelvic mass triage test
that achieved best in class accuracy (ROC-AUC) of 95.1% and is
being optimised.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called the HyCEAD Ziplex(R) platform and is based on a
patented flow through array technology. It provides for low cost,
highly multiplexed, rapid and sensitive capture of targets from a
wide variety of sample types. A proprietary chemistry approach
allows for the capture and amplification of over 100 biomarkers
simultaneously in a single reaction. The HyCEAD Ziplex system is
ideal for measuring gene expression and other markers directly from
Parsortix harvests and was used in the ovarian cancer pelvic mass
triage test to achieve the 95.1% accuracy.
ANGLE's proprietary technologies can be combined to provide
automated, sample to answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as QIAGEN, Abbott and
Philips, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
13 peer-reviewed publications and 23 publicly available posters,
available on our website.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORBUGDBLUGBGCI
(END) Dow Jones Newswires
January 09, 2019 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024